Literature DB >> 14730337

A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.

G Del Toro1, P Satwani, L Harrison, Y-K Cheung, M Brigid Bradley, D George, D J Yamashiro, J Garvin, D Skerrett, O Bessmertny, K Wolownik, C Wischhover, C van de Ven, M S Cairo.   

Abstract

Reduced intensity (RI) allogeneic stem cell transplantation (AlloSCT) was initially demonstrated in adults following HLA-matched family and unrelated adult donor AlloSCT. There is little information about RI AlloSCT in children. We report results of a pilot study of RI AlloSCT in 21 recipients (< or =21 years). Age: median 13 (0.5-21) years, 8F:13M, 14 unrelated cord blood units (UCB) (10 4/6, 4 5/6), two related BM (6/6, 5/6), four related PBSC (2 6/6, 2 5/6), and one related BM+PBSC (6/6). RI: fludarabine, busulfan (n=14); fludarabine, cyclophosphamide (n=4); fludarabine, melphalan (n=1); total body irradiation, fludarabine, cyclophosphamide (n=1); or fludarabine, cyclophosphamide, and etoposide (n=1). Graft-versus-host disease prophylaxis: FK506 0.03 mg/kg/day and mycophenolate mofetil 15 mg/kg/q 12 h. UCB median nuc/kg and CD34/kg was 4.3 x 10(7)/kg (0.9-10.8) and 1.9 x 10(5)/kg (0.3-6.9), and related BM/PBSC median nuc/kg and CD34/kg was 8.3 x 10(8) (4.7-18.9) and 5.0 x 10(6)/kg (4.6-6.4). Maximal chimerism following unrelated cord blood transplantation, 100% x 7, 98% x 1, 95% x 2, 55% x 1, and 0% x 3; related PBSC/BM, 100% x 5, 65% x 1, and 55% x 1. Graft failure occurred in 5/21 (24%). In summary, RI AlloSCT in children is feasible and tolerable (< or =25% GF) and results in > or =85% of recipients initially achieving > or =50% donor chimerism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730337     DOI: 10.1038/sj.bmt.1704399

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

2.  Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE.

Authors:  M Hirano; R Martí; C Casali; S Tadesse; T Uldrick; B Fine; D M Escolar; M L Valentino; I Nishino; C Hesdorffer; J Schwartz; R G Hawks; D L Martone; M S Cairo; S DiMauro; M Stanzani; J H Garvin; D G Savage
Journal:  Neurology       Date:  2006-09-13       Impact factor: 9.910

Review 3.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 4.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

5.  Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning.

Authors:  R Majzner; C Sandoval; A J Dozor; Z Jin; C van de Ven; R Dalal; E Morris; L Harrison; K Wolownik; S Fabricatore; L A Baxter-Lowe; M S Cairo
Journal:  Bone Marrow Transplant       Date:  2016-06-20       Impact factor: 5.483

6.  Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.

Authors:  A Lawitschka; M Faraci; I Yaniv; P Veys; P Bader; J Wachowiak; G Socie; M D Aljurf; M Arat; J J Boelens; R Duarte; A Tichelli; C Peters
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 7.  Stem and progenitor cells in human umbilical cord blood.

Authors:  Myoung Woo Lee; In Keun Jang; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

8.  Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.

Authors:  Mitchell S Cairo; Mary Gerrard; Richard Sposto; Anne Auperin; C Ross Pinkerton; Jean Michon; Claire Weston; Sherrie L Perkins; Martine Raphael; Keith McCarthy; Catherine Patte
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 9.  Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood.

Authors:  Angela R Smith; John E Wagner
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

10.  Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation.

Authors:  H C Toh; W K Chia; L Sun; C H Thng; Y Soe; Y P Phoon; S P Yap; W T Lim; W M Tai; S W Hee; S H Tan; S S Leong; E H Tan
Journal:  Bone Marrow Transplant       Date:  2010-07-26       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.